HRP20240282T1 - Upotreba kladribina za liječenje autoimune neuromuskularne bolesti - Google Patents

Upotreba kladribina za liječenje autoimune neuromuskularne bolesti Download PDF

Info

Publication number
HRP20240282T1
HRP20240282T1 HRP20240282TT HRP20240282T HRP20240282T1 HR P20240282 T1 HRP20240282 T1 HR P20240282T1 HR P20240282T T HRP20240282T T HR P20240282TT HR P20240282 T HRP20240282 T HR P20240282T HR P20240282 T1 HRP20240282 T1 HR P20240282T1
Authority
HR
Croatia
Prior art keywords
cladribine
use according
preparation
unit dose
treatment
Prior art date
Application number
HRP20240282TT
Other languages
English (en)
Croatian (hr)
Inventor
Konrad REJDAK
Original Assignee
Chord Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chord Therapeutics Sa filed Critical Chord Therapeutics Sa
Publication of HRP20240282T1 publication Critical patent/HRP20240282T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HRP20240282TT 2017-07-21 2018-06-28 Upotreba kladribina za liječenje autoimune neuromuskularne bolesti HRP20240282T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease
PCT/GB2018/051801 WO2019016505A1 (en) 2017-07-21 2018-06-28 USE OF CLADRIBINE FOR THE TREATMENT OF AUTOIMMUNE NEUROMUSCULAR DISEASE
EP18739593.4A EP3654989B1 (en) 2017-07-21 2018-06-28 Use of cladribine for treating autoimmune neuromuscular disease

Publications (1)

Publication Number Publication Date
HRP20240282T1 true HRP20240282T1 (hr) 2024-05-10

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240282TT HRP20240282T1 (hr) 2017-07-21 2018-06-28 Upotreba kladribina za liječenje autoimune neuromuskularne bolesti

Country Status (16)

Country Link
US (2) US12171775B2 (OSRAM)
EP (2) EP3654989B1 (OSRAM)
JP (1) JP7186214B2 (OSRAM)
CA (1) CA3095893A1 (OSRAM)
DK (1) DK3654989T3 (OSRAM)
ES (1) ES2974423T3 (OSRAM)
FI (1) FI3654989T3 (OSRAM)
GB (1) GB2564717A (OSRAM)
HR (1) HRP20240282T1 (OSRAM)
HU (1) HUE066238T2 (OSRAM)
LT (1) LT3654989T (OSRAM)
PL (1) PL3654989T3 (OSRAM)
PT (1) PT3654989T (OSRAM)
RS (1) RS65246B1 (OSRAM)
SI (1) SI3654989T1 (OSRAM)
WO (1) WO2019016505A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) * 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
WO2025125527A1 (en) 2023-12-14 2025-06-19 Ares Trading S.A. Cladribine regimen for treating myasthenia gravis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
WO2001007054A1 (en) * 1999-07-22 2001-02-01 Supergen, Inc. Methods for treating autoimmune diseases
EP1556010A4 (en) * 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
EP1588283A2 (en) * 2002-11-22 2005-10-26 Transclick, Inc. System and method for language translation via remote devices
EA009714B1 (ru) 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
ES3007339T3 (en) 2004-12-22 2025-03-19 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EA020805B1 (ru) * 2006-05-24 2015-01-30 Мерк Сероно С.А. Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза

Also Published As

Publication number Publication date
DK3654989T3 (da) 2024-02-26
LT3654989T (lt) 2024-03-25
WO2019016505A1 (en) 2019-01-24
RS65246B1 (sr) 2024-03-29
GB2564717A (en) 2019-01-23
JP7186214B2 (ja) 2022-12-08
SI3654989T1 (sl) 2024-06-28
US20250302858A1 (en) 2025-10-02
HUE066238T2 (hu) 2024-07-28
GB201711800D0 (en) 2017-09-06
EP4292663A2 (en) 2023-12-20
JP2020527156A (ja) 2020-09-03
PL3654989T3 (pl) 2024-05-20
EP3654989A1 (en) 2020-05-27
US12171775B2 (en) 2024-12-24
FI3654989T3 (fi) 2024-03-21
ES2974423T3 (es) 2024-06-27
EP4292663A3 (en) 2024-03-20
EP3654989B1 (en) 2024-01-03
US20200163986A1 (en) 2020-05-28
CA3095893A1 (en) 2019-01-24
PT3654989T (pt) 2024-02-28

Similar Documents

Publication Publication Date Title
KR101900520B1 (ko) 복합 조성물
HRP20200991T1 (hr) Modulator androgenog receptora u kombinaciji s abirateron acetatom i prednizonom za liječenje karcinoma prostate
HRP20240082T1 (hr) Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
MY204827A (en) Semaglutide in medical therapy
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
JP2018138596A5 (OSRAM)
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
HRP20240282T1 (hr) Upotreba kladribina za liječenje autoimune neuromuskularne bolesti
CN102872238A (zh) 一种治疗骨关节疾病的药物及其制备方法
JP2016505050A5 (OSRAM)
HRP20180071T4 (hr) Upotreba kladribina u liječenju očnog neuromijelitisa
MX2024015351A (es) Composicion farmaceutica para tratar y resistir a la coagulacion sanguinea y uso de la misma
ZA202101688B (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
RU2015119223A (ru) Система дозированного распределения
CN106806438A (zh) 一种治疗痛风的中药组合物颗粒剂
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
EP4389218A3 (en) Composition for treating joint disease and kit containing same
JPS5942649B2 (ja) 重症筋無力症治療剤
CN103083500A (zh) 一种治疗弓形虫病的中药组合物
JP2020527156A5 (OSRAM)
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
CN104667137A (zh) 治疗乳腺小叶增生的中药配方
CN101518521A (zh) 雪松醇的医药新用途
RU2013124994A (ru) КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ